Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKUR vs LGND: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LGND Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LGND Overall Winner 6-Pillar Tally: OKUR 0 – 6 LGND Matrix Metrics: OKUR 1 – 9 LGND

As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin).

  • Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKUR vs LGND
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67
LGND NASDAQ Head-to-Head Winner
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$286.85
-0.03% 1D
Market Cap $5.7B
TTM Revenue $254M
Forward P/E 24.0x
Beta / 30D Vol 0.93β · 38% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 67.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $307.95 · SMA50: $302.35

6-Pillar Scorecard Institutional Category Breakdown (OKUR 0 – 6 LGND)

Columns: Metric · OKUR · LGND
1. Valuation Multiples LGND
Forward P/E N/M 24.0x
Trailing P/E N/M 115.2x
PEG Ratio N/M 1.53x
EV / Revenue N/M 26.9x
2. Growth & Scale LGND
Revenue Growth (YoY) +0.0% -31.8%
Earnings Growth (YoY) +0.0% +825.0%
TTM Revenue (USD) N/A $254M
Market Cap $113.7M $5.7B
3. Profitability & Quality LGND
Gross Margin N/A 86.1%
Operating Margin 0.0% 14.4%
Net Profit Margin 0.0% 20.3%
Return on Equity (ROE) -55.2% 5.4%
4. Balance Sheet & Cash Flow LGND
Cash Generation (TTM) -$48M $57M
Cash Flow Margin N/A 22.6%
Net Cash / Leverage $151M Net Cash $1.10B Net Debt (1.20x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LGND
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 89.1% (100th %ile) 45.4% (9th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat LGND
OpEx & R&D Intensity N/A 71.7% of Rev ($182M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKUR (1) vs LGND (9)
Institutional Metric OKUR LGND Criterion Row Edge
Market Capitalization
Scale
$113.7M $5.7B Larger Scale LGND
Trailing P/E Ratio
Valuation
N/M 115.2x Lower Multiple LGND
Forward P/E Ratio
Valuation
N/M 24.0x Lower Multiple LGND
Revenue Growth (YoY)
Growth
+0.0% -31.8% Higher Growth OKUR
Operating Margin (TTM)
Profitability
0.0% 14.4% Higher Margin LGND
Net Profit Margin
Profitability
0.0% 20.3% Higher Margin LGND
Return on Equity (ROE)
Capital Efficiency
-55.2% 5.4% Higher ROE LGND
52-Week Range Position
Momentum
20% ($2–$5) 74% ($176–$327) Stronger Trend LGND
Beta / 30D Volatility
Risk Regime
0.96β · 100% Vol 0.93β · 38% Vol Lower Realized Risk LGND
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 46.5 / 100 (HOLD) Higher Composite LGND
Trailing 12M Revenue (USD)
Operating Scale
N/A $254M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.53x PEG · 26.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($151M Net Cash) $57M ($1.10B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKUR +11.46 pp
OKUR: +4.65% · LGND: -6.81%
3M Horizon LGND +32.97 pp
OKUR: -30.59% · LGND: +2.38%
6M Horizon LGND +60.95 pp
OKUR: -35.87% · LGND: +25.08%
1Y Horizon LGND +41.38 pp
OKUR: -2.17% · LGND: +39.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs LGND. Trailing 12-month operating profitability (OKUR 0.0% vs LGND 14.4%) and valuation multiples (OKUR N/M vs LGND 24.0x Forward P/E) are benchmarked directly in Pillar 4 below.

OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M
LGND ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin86.1%
Op. Margin14.4%
ROE / Fwd P/E5.4% · 24.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LGND CONSOLIDATION
102d in phase · OBV DISTRIBUTION
Current IV 45.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LGND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LGND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.7B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 71.7% of Rev ($182M)
90D Engineering Disclosures 0 Published

Investor FAQ OKUR vs LGND Key Questions & Quantitative Answers

As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin). Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LGND leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LGND at -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $254M for LGND. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus 71.7% of Rev ($182M) (0 disclosures) for LGND.

LGND screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LGND trades at 24.0x Forward P/E, 115.2x Trailing P/E, 1.53x PEG, and 26.9x EV/Revenue (22.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus LGND (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, LGND carries 45.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.93β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.